Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298094 | 1.00 | KCNN4 (0.43) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL992573 | 1.00 | KCNN4 (0.43) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL6036541 | 0.89 | KIF11 (0.39) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL29276034 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL26062663 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL31696759 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL5200976 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL3548775 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL3548773 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL6399801 | 0.86 | NR1H2 (0.46) | MMP2ANPEPCYP1A2CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461315-B1 | CATALYTIC CARBONYLATION OF THREE AND FOUR MEMBERED HETEROCYCLES | CORNELL RES FOUNDATION INC (US) | 2009-07-29 | — | — | EP | claimed |
| EP-3710458-B1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12312370-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-3256218-B1 | A KDM1A INHIBITOR AND ITS USE IN THERAPY | IMAGO BIOSCIENCES INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240175019-A1 | Skeletal Muscle Delivery Platforms and Methods of Use | Arrowhead Pharmaceuticals, Inc. | 2024-05-30 | — | — | US | disclosed |
| CN-111491938-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240076270-A1 | INTEGRIN LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2024-03-07 | — | — | US | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| CN-107427699-A | For treating the KDM1A inhibitor of disease | 伊美格生物科学公司 | 2017-12-01 | — | — | CN | disclosed |
| US-20170210778-A1 | NOVEL COMPOUNDS | INVIVOGEN SAS (FR) | 2017-07-27 | — | — | US | disclosed |
| WO-2017070794-A1 | PROCESS FOR THE PREPARATION OF 2-[2-(2-AMINO-2-CARBOXY-ETHYLAMINO)-2-CARBOXY-ETHYLAMINO]-SUCCINIC ACID (AM-A) AND ANALOGS AND DERIVATIVES THEREOF | MCMASTER UNIVERSITY (CA) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017035417-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| WO-2016130952-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
| US-8933065-B2 | N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-01-13 | — | — | US | disclosed |
| EP-2262764-B1 | NOVEL N-BENZYLAMIDE SUBSTITUTED DERIVATIVES OF 2-(ACYLAMIDO)ACETIC ACID AND 2-(ACYLAMIDO)PROPIONIC ACIDS: POTENT NEUROLOGICAL AGENTS | UNIV NORTH CAROLINA (US) | 2014-11-12 | — | — | EP | disclosed |
| US-20110021482-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE | 2011-01-27 | — | — | US | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021482-A1 | Novel N-Benzylamide Substituted Derivatives of 2-(Acylamido)acetic Acid and 2-(Acylamido)propionic Acids: Potent Neurological Agents | NAAA, AADAC, GBA1 | KCNN4 757/4885MMP2 2322/4885KMT2A 943/4885 |
| US-20240199655-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | KCNN4 4276/4885MMP2 1234/4885KMT2A 1002/4885 |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | KCNN4 3561/4885MMP2 625/4885KMT2A 4148/4885 |
| US-12312370-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | KCNN4 4276/4885MMP2 1234/4885KMT2A 1002/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | KCNN4 4639/4885MMP2 2512/4885KMT2A 1548/4885 |
| US-20240076270-A1 | INTEGRIN LIGANDS AND USES THEREOF | ITGAV, ITGA6, ITGB6 | KCNN4 4202/4885MMP2 1100/4885KMT2A 4140/4885 |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | KCNN4 3814/4885MMP2 4421/4885KMT2A 14/4885 |
| US-20240175019-A1 | Skeletal Muscle Delivery Platforms and Methods of Use | MUSK, MYLK2, ITGB6 | KCNN4 4488/4885MMP2 1456/4885KMT2A 3095/4885 |
| US-20170210778-A1 | NOVEL COMPOUNDS | F12, C1R, F11 | KCNN4 4428/4885MMP2 4405/4885KMT2A 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.